Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Viragen (Europe) Ltd. (OTC BB:VERP.OB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Financials
Location
865 SW 78th Avenue, Suite 100
Plantation, FL 33324
Phone: (954) 233-8377
Fax: (954) 233-1414
Employees (last reported count): 31
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Related Links
 ·Search Yahoo! for related links...
Ownership
·Insider and 5%+ Owners: 91%
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Viragen (Europe) Ltd., an 89% owned subsidiary of Viragen, Inc., is in the business of researching, developing and manufacturing products that help the human immune system resist viral infections, and related technologies. The Company, through a license granted by its parent company Viragen, Inc., has certain exclusive rights in the European Union and certain non-exclusive rights throughout the rest of the world, excluding the United States and its territories, to engage in the manufacture and distribution of certain immunological products, particularly human leukocyte derived interferon. The license encompasses Viragen, Inc.'s Omniferon product, a natural interferon product. Natural interferon stimulates and controls the human immune system. In addition, interferon may stem the growth of various viruses including those involved with diseases like hepatitis, cancer, multiple sclerosis, and HIV/AIDS.
More from Market Guide: Expanded Business Description

Financial Summary
Viragen, and its subsidiaries, are involved in the research, development and manufacture of certain immunological products for commercial application. For the nine months ended 3/31/01, revenues rose from $459 to $146 thousand. Net loss rose 10% to $5.4 million. Revenues reflect export sales of OMNIFERON. Higher loss reflects increased general and administrative expenses and higher R&D costs related to the OMNIFERON product and collaborative agreements.
More from Market Guide: Significant Developments

Officers
FY2000 Pay

Gerald Smith, 69
Chairman, Pres, CEO
$82K
D. Magnus Nicolson, 40
COO, Director and Managing Director of Viragen (Scotland) Ltd.
170K
Dennis Healey, 52
Exec. VP, Treasurer, Sec., Director
57K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- OTC BB:VERP.OBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$0.453
Recent Price$0.90 
52-Week High
on 5-Dec-2000
$3.313
Beta-0.69 
Daily Volume (3-month avg)4,636 
Daily Volume (10-day avg)2,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+2.9%
52-Week Change
relative to S&P500
+38.0%
Share-Related Items
Market Capitalization$23.3M
Shares Outstanding25.9M
Float2.30M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.00 
Earnings (ttm)-$0.31 
Earnings (mrq)-$0.08 
Sales (ttm)$0.01 
Cash (mrq)$0.07 
Valuation Ratios
Price/Book (mrq)222.04 
Price/EarningsN/A 
Price/Sales (ttm)121.05 
Income Statements
Sales (ttm)$163.0K
EBITDA (ttm)-$6.44M
Income available to common (ttm)-$6.87M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-99.12%
Return on Equity (ttm)-500.95%
Financial Strength
Current Ratio (mrq)2.32 
Debt/Equity (mrq)0.10 
Total Cash (mrq)$1.69M
Short Interest
As of 8-Feb-1999
Shares Short2,000 
Percent of Float0.1%
Shares Short
(Prior Month)
0 
Short Ratio0.14 
Daily Volume14.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.